spacer gif spacer gif spacer gif spacer gif spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    


This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saliba, R. S.
Right arrow Articles by Cheetham, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saliba, R. S.
Right arrow Articles by Cheetham, M. E.

The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation

Richard S. Saliba1, Peter M. G. Munro2, Philip J. Luthert1 and Michael E. Cheetham1,*

1 Division of Pathology, Institute of Ophthalmology, University College London, London, UK
2 Electron Microscopy, Institute of Ophthalmology, University College London, London, UK



View larger version (48K):

[in a new window]
 
Fig. 1. Mutant opsin accumulates in a structure close to the Golgi apparatus. The cellular localisations of opsin in transiently transfected COS-7 cells expressing WT opsin and WT opsin with a C-terminal GFP tag (WT-GFP) were compared with mutant opsin (P23H-opsin) and GFP-tagged mutant opsin (P23H-GFP) by confocal immunofluorescence. The intracellular opsin colocalised with the Golgi marker ß-COP; however, in cells with mutant opsin inclusions, the ß-COP staining is dispersed. Bar, 10 µm.

 


View larger version (49K):

[in a new window]
 
Fig. 2. Mutant opsin does not accumulate in the Golgi. Cells expressing WT (WT-GFP) and mutant (P23H-GFP) opsin tagged with GFP were treated with BFA (20 µg/ml for 15 minutes prior to fixation). BFA dispersed the Golgi (ß-COP) and the WT-GFP opsin that was trafficking through the Golgi but did not disperse the P23H-GFP opsin from its juxtanuclear position. Bar, 10 µm.

 


View larger version (52K):

[in a new window]
 
Fig. 3. Mutant opsin inclusions have the characteristics of an aggresome. Mutant opsin (P23H-GFP) colocalised with c-myctagged ubiquitin when co-transfected in COS-7 cells. The P23H-GFP opsin inclusions led to the disruption of the intermediate filament network (Vimentin). The cytoplasmic chaperone Hsc70 was recruited to the P23H-GFP inclusions. Bar, 10 µm.

 


View larger version (163K):

[in a new window]
 
Fig. 4. Ultrastructure of opsin aggresomes. Electron micrograph of a COS-7 cell with a P23H-GFP mutant aggresome. (i) The aggresome (A) forms near the nucleus (N) and centrosome (C) and is surrounded by mitochondria (M). (ii) At higher magnification the intermediate filaments (IF) that surround the aggresome can be seen. (iii) The aggresome also has a high membrane content and in places appears to be surrounded by membrane (arrowheads). Bar, 1 µm.

 


View larger version (29K):

[in a new window]
 
Fig. 5. Co-transfection of normal and mutant opsin leads to the recruitment of the normal protein to the mutant opsin aggresome. (A) GFP-tagged WT opsin in pEGFP was co-transfected with untagged WT opsin in pMT3 (WT-GFP/WT-opsin) at a vector ratio of 1:10. Cells showed no increase in aggresome formation compared with WT-GFP alone, whereas co-transfection of GFP-tagged WT opsin in pEGFP with untagged P23H opsin in pMT3 (WT-GFP/P23H-opsin) at a vector ratio of 1:10 increased the percentage of WT opsin recruited to aggresomes, as judged by GFP fluorescence. Bar, 10 µm. (B) Quantification of co-transfection aggresome formation after 24 hours of opsin expression. The percentage of cells with WT-GFP fluorescence aggresomes was counted double blindly from four separate experiments (error bars±2 s.d.). BFA (20 µg/ml for 15 minutes prior to fixation) was added to both experiments to reduce confusion over WT opsin in the secretory pathway.

 


View larger version (75K):

[in a new window]
 
Fig. 6. Inhibition of the proteasome leads to an increase of mutant opsin ER staining. Confocal immunofluorescence shows that inhibition of the proteasome machinery with MG-132 (5 µM for 8 hours) did not affect the processing of WT opsin. The treatment led to an increase in the level of P23H and K296E mutant opsin in the ER, as shown by colocalisation with the ER-resident Hsp70, BiP. Bar, 10 µm.

 


View larger version (51K):

[in a new window]
 
Fig. 8. Inhibition of N-linked glycosylation leads to an increase of mutant opsin ER staining. The colocalisation of WT (WT-opsin) and mutant opsins (P23H-opsin and K296E-opsin) with the ER marker calnexin in untreated cells is shown in the top row (Untreated). Inhibition of protein glycosylation with tunicamycin (0.8 µg/ml for 8 hours) led to an increase in the level of mutant protein retained within the ER. The trafficking of the WT protein (WT-opsin) to the plasma membrane was not affected by the treatment with tunicamycin and showed no increase in ER staining. By contrast, the mutant proteins (P23H-opsin and K296E-opsin) accumulated in the ER as shown by colocalisation with the ER-membrane-bound lectin chaperone calnexin. Bar, 10 µm.

 


View larger version (57K):

[in a new window]
 
Fig. 7. Inhibition of the proteasome leads to an increase in mutant opsin. Western blot using mAb 1D4 of opsin in DM-soluble (S) and DM-insoluble (P) protein extracts showed that inhibition of the proteasome machinery with MG-132 (5 µM for 16 hours) (+) led to an increase in the steady state level of mutant opsin in COS-7 cells. The level of WT protein (WT-opsin) was not affected by proteasome inhibition, whereas the level of mutant proteins (P23H-opsin and K296E-opsin) showed a dramatic increase. The electrophoretic mobilities of different glycoforms of opsin were determined empirically using PNGase F and Endo H: mature (~40 kDa) (arrowhead); and immature forms (>41 kDa); deglycosylated form (~30 kDa) (*) and dimer (~60 kDa) (**). Blot exposures have been adjusted to give equivalent band intensity between WT and mutants, as the WT protein is far more abundant. The positions of the molecular weight markers are indicated on the left in kDa.

 


View larger version (80K):

[in a new window]
 
Fig. 9. Inhibition of N-linked glycosylation prevents the degradation of mutant opsin. A western blot using mAb 1D4 of opsin in total protein extracts showed that inhibition of protein glycosylation with tunicamycin (0.8 µg/ml for 16 hours) led to an increase in the steady state level of mutant protein. The level of total WT opsin was not noticeably altered, whereas the level of mutant (P23H-opsin and K296E-opsin) increased significantly after treatment. The electrophoretic mobilities of different glycoforms of opsin were determined empirically using PNGase F and Endo H: mature (~40 kDa) (arrowhead); and immature forms (>41 kDa); deglycosylated form (~30 kDa) (*) and dimer (~60 kDa) (**). Blot exposures have been adjusted to give equivalent band intensity between WT and mutants. The positions of the molecular weight markers are indicated on the left in kDa.

 


View larger version (76K):

[in a new window]
 
Fig. 10. Treatment with 9-cis-retinal leads to an increase in soluble mutant opsin that reaches the plasma membrane. (A) Confocal immunofluorescence showing that overnight treatment of COS-7 cells expressing P23H-opsin leads to an increase in the amount of protein that reaches the plasma membrane. Bar, 10 µm. (B) A western blot using mAb 1D4 of P23H-opsin in total (T), DM-soluble (S) and DM-insoluble (P) protein extracts shows that the addition of 9-cis-retinal (+) dramatically increases the amount of opsin in the cells and that most of this is in the soluble fraction. The electrophoretic mobilities of different glycoforms of opsin are indicated: mature (~40 kDa) (arrowhead); and immature forms (>41 kDa); deglycosylated form (~30 kDa) (*) and dimer (~60 kDa) (**). The positions of the molecular weight markers are indicated on the left in kDa.

 





© The Company of Biologists Ltd 2002